Sun Life U.S. Partners with Medzown to Expand Clinical Trial Access for High-Cost Conditions
Event summary
- Sun Life U.S. and Medzown are collaborating to increase access to clinical trials for employees at self-insured employers.
- Medzown's AI-powered clinical model will identify patients with cancer and complex conditions for appropriate clinical trials.
- Sun Life's 2026 high-cost claims report shows cancer costs average $252,000 per individual per year, while ortho/MSK costs average $120,000.
- Medzown's Predictive Population Analytics platform proactively recognizes members who may benefit from advanced treatment options.
- The partnership aims to address high-cost claims before they escalate and reduce long-term specialty drug costs for employers.
The big picture
This collaboration aligns with the growing trend of insurers leveraging precision medicine to manage high-cost conditions. Sun Life U.S., as the largest independent stop-loss provider, is expanding its health solutions to improve outcomes and contain costs for self-insured employers. The partnership with Medzown underscores the strategic shift towards proactive, data-driven healthcare management.
What we're watching
- Cost Reduction Impact
- How effectively the partnership will reduce high-cost claims for self-insured employers.
- Clinical Trial Access
- The pace at which Medzown's AI-powered model can identify and connect patients to appropriate clinical trials.
- Market Differentiation
- Whether Sun Life can sustain a competitive edge by expanding its suite of health solutions.
Related topics